THC · Tenet Healthcare Corporation New

The thesis

Tenet Healthcare's hospital-margin improvement is intact on the numbers reported so far, and the shares have recovered to within 3.6% of their 52-week high. The third-quarter report on 29 October 2026 settles whether the second-quarter margin gain lasts. The shares closed at $270.63 on 22 October 2026, against a 52-week high of $280.77 set on 21 August 2026 and the 25 September 2026 close of $259.71.

Tenet's 23 July 2026 second-quarter release reported a hospital adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) margin of 18.0%. It raised full-year adjusted EBITDA guidance to $4.830–5.030 billion. No company filing or release since then changes those figures.

The narrative is maturing: the story is well known, the main wave of analyst target increases came in the week of 27 July 2026, and one further raise, Guggenheim's on 16 October 2026, shows the buying case is still being updated ahead of the report. The shares rose 11.2% over the three months to 22 October 2026, a much slower pace than the 43.6% gain recorded to 9 October 2026, because the 24 July 2026 post-earnings jump has left the three-month window.

Bullish and bearish views on Tenet Healthcare Corporation New

The bull case on Tenet Healthcare Corporation New (THC), in brief: Hospital margin has a disclosed anchor. The bear case: The price has not cleared the high.

Bull case

• Hospital margin has a disclosed anchor. Second-quarter hospital adjusted EBITDA was $762 million at an 18.0% margin, against $623 million and 15.6% a year earlier (Tenet release, 23 July 2026). Same-hospital admissions rose 2.3%.
• Guidance was raised and can be checked. Tenet lifted 2026 adjusted EBITDA guidance to $4.830–5.030 billion and adjusted free cash flow to $2.725–3.025 billion on 23 July 2026. The 29 October 2026 report shows whether the company holds or raises those ranges.
• Analyst targets sit above the price. Guggenheim raised its target to $307 on 16 October 2026, from $283 on 28 July 2026 (Benzinga). UBS set $308 (27 July 2026), Truist $290 (28 July 2026) and RBC $283 (27 July 2026). The 22 October 2026 close of $270.63 is below each.
• Earnings beat was large. MarketBeat reported second-quarter adjusted earnings of $6.12 a share against a consensus of $4.26 on 23 July 2026. The shares rose 17.3% to $233.54 in the 24 July 2026 session (Benzinga).
• Financing is out of the way. A Form 8-K dated 22 September 2026 records $2.0 billion of 6.250% senior notes due 2034. Tenet stated it intends to use the proceeds and cash to redeem $1.5 billion due 2027 and $0.5 billion due 2028.

Bear case

• The price has not cleared the high. The shares closed at $270.63 on 22 October 2026 against the $280.77 high of 21 August 2026. They have not returned to that level in the nine weeks since.
• Ambulatory growth leaned on price per case. Same-facility surgical cases fell 1.2% in the second quarter while revenue per case rose 6.3%. The segment's adjusted EBITDA margin was 39.0% against 39.2% a year earlier (Tenet release, 23 July 2026).
• Payer mix and policy carry weight. Tenet's release cited lower exchange admissions and lower Medicaid supplemental revenue in hospital results. Benzinga reported on 5 October 2026 that the Federal Trade Commission sent letters warning hospitals against deceptive pricing practices; the letters' content and reach were not available for this note.
• Not all EBITDA is common-shareholder earnings. The 2026 outlook includes $910–960 million of net income available to noncontrolling interests, so consolidated adjusted EBITDA overstates what accrues to common shareholders.
• Some analysts see less upside. BMO Capital initiated at Market Perform with a $265 target on 23 September 2026, and Baird kept Neutral with a $280 target on 28 July 2026 (Benzinga). Both are at or near the current price.

Price setup

The shares closed at $270.63 on 22 October 2026, 3.6% below the 52-week high of $280.77 (adjusted daily closes). The 14-day relative strength index was 64.4, up from 53.4 on 9 October 2026 and below the 70 level commonly read as overbought. The close sits $10.92 above the 25 September 2026 close of $259.71, which marks the recent low.

Crowding evidence is limited to two observable items. Unusual Whales, in data dated 6 October 2026, showed the options market pricing a move of about 11.4% (±$29.45) around the earnings report. Benzinga ran a 29 July 2026 piece naming overbought health care stocks after the July run-up.

A close above $280.77 would be a new 52-week high. A close below $259.71 would end the recovery from the September low.

Catalysts, next 30 days

No upcoming dated catalysts on file — the dated entries below have passed.

Elapsed catalysts

• 29 October 2026: third-quarter 2026 results. Tenet reports before the market opens, with a call at 10:00 a.m. Eastern (Tenet announcement via Finviz). The report shows the hospital margin against 18.0% and whether the $4.830–5.030 billion EBITDA range is kept, raised or cut. (passed 8d ago)
• After 29 October 2026: analyst target revisions. Targets of $307–$308 at Guggenheim and UBS, and $265 at BMO, will be reset against the new figures. (passed 8d ago)

What would change the view

The operating case breaks if third-quarter hospital adjusted EBITDA margin falls below the 18.0% reported for the second quarter, or if Tenet cuts the $4.830–5.030 billion full-year range. Surgical cases falling by more than the second-quarter 1.2% with revenue-per-case growth under 6.3% would show the ambulatory price offset fading. A second mention of lower exchange admissions or Medicaid supplemental revenue alongside a lowered outlook would show payer mix outweighing admissions growth.

On price, a weekly close below $259.71 would end the recovery from the September low. A close above $280.77 with guidance held or raised would strengthen the case.

What it trades with

Tenet trades with US hospital operators and, more loosely, with managed-care names, because payer mix, exchange enrollment and Medicaid funding drive both. Policy headlines on hospital pricing, such as the FTC letters reported on 5 October 2026, can move the group together. The 24 July 2026 jump in Tenet occurred on company-specific results, with the S&P 500 up 0.04% that day (Benzinga).